Area of research
Oncology · Cancer Research
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Pancreatic and Hepatic Oncology Research, Cancer Genomics and Diagnostics, and Cancer Cells and Metastasis.
Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer
765 NG-350A, a tumor-selective anti-CD40 agonist expressing therapeutic, gemcitabine/nab-paclitaxel and ipilimumab for untreated metastatic pancreatic adenocarcinoma: cohort C of the REVOLUTION trial
Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial
An NK-like CAR T cell transition in CAR T cell dysfunction
Challenges and Opportunities for Pancreatic Cancer Immunotherapy
CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study
Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer
Safety and Pharmacokinetics of CXCR4 Peptide Antagonist, LY2510924, in Combination with Durvalumab in Advanced Refractory Solid Tumors
Early treatment-related neutropenia predicts response to palbociclib
Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer
Abstract CT004: A Phase Ib study of CD40 agonistic monoclonal antibody APX005M together with gemcitabine (Gem) and nab-paclitaxel (NP) with or without nivolumab (Nivo) in untreated metastatic ductal pancreatic adenocarcinoma (PDAC) patients